Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.
- First complete response in BTKi-resistant follicular lymphoma
- Azer-cel combined with BTKi targets a $12 billion market
- Trial ongoing across US and Australian sites
- Azer-cel offers off-the-shelf CAR T therapy advantage
- Four patients dosed in BTKi combination cohort so far
Complete Response in Challenging Follicular Lymphoma Case
Imugene Limited (ASX:IMU) has reported a complete response (CR) in the first patient treated within the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its Phase 1b azer-cel trial. This patient, diagnosed with follicular lymphoma (FL), had previously failed BTKi therapy, a common but increasingly limited treatment option for B-cell malignancies.
FL remains the most prevalent indolent B-cell lymphoma with a high relapse rate despite initial treatment success. Patients who develop resistance to BTKi therapies face a significant clinical void, making this response a noteworthy milestone in a population with few alternatives.
Azer-cel’s Potential to Overcome BTKi Resistance
The trial’s BTKi cohort explores whether combining azer-cel, an allogeneic CAR T cell therapy, with BTKi drugs can restore or enhance treatment efficacy. Azer-cel targets the CD19 antigen on malignant B cells and is derived from healthy donor T cells, enabling rapid off-the-shelf administration without the lengthy manufacturing delays of autologous CAR T therapies.
Leslie Chong, Imugene’s CEO, emphasised that this initial positive data bolsters confidence in azer-cel’s potential for patients who have exhausted standard treatments, including BTKi options. Given the widespread use of BTKi therapies, this combination approach could represent a meaningful new pathway for azer-cel’s clinical development.
Expanding Trial Across Multiple Sites and Indications
The Phase 1b trial is actively enrolling patients across ten US and five Australian sites, targeting a broad spectrum of B-cell malignancies such as FL, chronic lymphocytic leukemia, mantle cell lymphoma, and others. To date, four patients have been dosed in the BTKi combination cohort, including the first patient with mantle cell lymphoma.
The global BTKi market was valued at approximately US$12 billion in 2025, underscoring the commercial significance of addressing resistance in this space. The trial’s early safety profile remains manageable and well tolerated, with meaningful clinical responses already observed.
Azer-cel’s Off-the-Shelf Advantage in CAR T Therapy
Azer-cel’s allogeneic design allows it to be administered within days, a stark contrast to autologous CAR T therapies which require a three-to-six-week manufacturing lead time. This rapid availability could be critical for patients with aggressive or resistant disease.
As the dataset matures, Imugene plans to provide further updates on efficacy and safety outcomes. The company’s recent regulatory progress, including FDA Fast Track designation for other blood cancers, complements this clinical momentum.
Bottom Line?
While early, this complete response in a BTKi-resistant patient hints at azer-cel’s potential to fill a critical gap in lymphoma treatment, warranting close attention to upcoming trial data.
Questions in the middle?
- Will subsequent patients in the BTKi cohort replicate this complete response?
- How durable will the responses be over longer-term follow-up?
- What regulatory milestones could accelerate azer-cel’s path to market?